V3 BWC: BioFR!
Today’s Change (Mar 17, 2026)
—
A symphony is an automated trading strategy — Learn more about symphonies here
About
A daily, rule-based multi-asset strategy that cleverly rotates biotech bets (LABU/LABD) with tech/leveraged plays and macro hedges. It uses momentum signals (RSI and related metrics) to pick top assets within blocks, includes a risk-off Safety Mix, and rebalances every day to chase strength while trying to limit losses.
- Every day, the strategy evaluates a large set of signals across many assets, using simple momentum ideas (momentum-ish indicators like RSI) and performance over short windows.
- It builds groups (like a biotech block and a Safety Mix block) and selects top assets within each group based on recent strength or downstream rules.
- Biotech tilt: LABU (bull biotech) gets significant weight when signals align; LABD (bear biotech) can be used in opposing conditions. Individual biotech-related names and biotech-exposed vehicles may be rotated in and out.
- Tech/levered plays: positions like TECL, TQQQ, and related tech/levered instruments are considered when momentum is strong.
- Macro/bond/risk-off layers: other parts of the portfolio use bond-related ETFs (IEF, AGG, BND, TLT) and hedges like UVXY (volatility) or core safe assets (GLD, USDU, UUP) depending on signals.
- A rotating “Rotator” picks one or a few assets (e.g., LLY, AVGO, TLT) based on short-window strength, and allocates weight to the winner.
- The “Safety Mix” and “Normal market” blocks evaluate a basket of assets by a rule set (top by cumulative return, standard deviation, or other metrics) to form a diversified risk-off sleeve when needed.
- Rebalance is daily, so the composition can shift a lot from day to day depending on signals.
- Overall goal: tilt toward biotech upside opportunities while using macro risk controls and hedges to manage drawdowns, with a bias toward aggressive exposure via leverage in certain blocks.
Dynamic, daily-rotating biotech/tech strategy with macro hedges. Lower beta (~0.63) and positive OOS alpha offer diversification and potential protection versus the S&P 500, though stress periods can generate larger drawdowns.
1M
3M
6M
YTD
1Y
3Y
Max
Performance
Compared to selected benchmarks
| Alpha | Beta | R2 | R | |
|---|---|---|---|---|
| 0.75 | 0.72 | 0.07 | 0.27 |
Performance Metrics
| Cumulative Return | Annualized Return | Trailing 1M Return | Trailing 3M Return | Sharpe Ratio | |
|---|---|---|---|---|---|
| 281.26% | 13.8% | -1.77% | 0.2% | 0.81 | |
| 203,297.37% | 108.71% | -2.58% | -4.4% | 1.76 |
Initial Investment
$10,000.00
Final Value
$20,339,737.23Regulatory Fees
$117,518.58
Total Slippage
$823,567.15
Invest in this strategy
OOS Start Date
Apr 4, 2024
Trading Setting
Daily
Type
Stocks
Category
Multi-asset, tactical rotation, biotech focus, leveraged etfs, risk management
Tickers in this symphonyThis symphony trades 33 assets in total
Ticker
Type
AGG
iShares Core U.S. Aggregate Bond ETF
Stocks
AMD
Advanced Micro Devices
Stocks
AVGO
Broadcom Inc. Common Stock
Stocks
BIB
ProShares Ultra NASDAQ Biotechnology
Stocks
BIS
ProShares UltraShort NASDAQ Biotechnology
Stocks
BND
Vanguard Total Bond Market
Stocks
GLD
SPDR Gold Trust, SPDR Gold Shares
Stocks
IEF
iShares 7-10 Year Treasury Bond ETF
Stocks
IWM
iShares Russell 2000 ETF
Stocks
KLAC
KLA Corporation Common Stock
Stocks